Dyadic International, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Dyadic International, Inc. now
Current reporting with the operating signal separated from the noise.
Dyadic International, Inc.: Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas
The story matters when it changes Dyadic International, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Dyadic International, Inc.: Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement
The development tests whether Dyadic International, Inc. can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.Dyadic International, Inc. (DYAI) Q3 2025 Earnings Call Transcript
Investors are testing whether Dyadic International, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.UPDATE: Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock
Investors are testing whether Dyadic International, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Dyadic International, Inc. Announces Proposed Public Offering of Common Stock
Investors are testing whether Dyadic International, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions
The story matters when it changes Dyadic International, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
The story matters when it changes Dyadic International, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Dyadic International, Inc. (DYAI) Announces Board and Management Changes
The development tests whether Dyadic International, Inc. can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.Latest DYAI filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Dyadic International, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
SEARCH Q2 COVERAGE →Third quarter
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →